Etelcalcetide Trial in Children with Kidney Disease
Phase 3
56
about 9.8 years
0–18
10 sites in CA, CO, MO +6
What this study is about
Researchers are testing a treatment called Etelcalcetide in children with kidney disease and high parathyroid hormone levels. This treatment aims to help manage these conditions, which can cause bone problems and other complications. The trial will last for about 3 years.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Etelcalcetide
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
etelcalcetide
injection (Injection)
Primary: Percentage Change from Baseline in Mean iPTH During the EAP
Secondary: Change from Baseline in Diastolic Blood Pressure, Change from Baseline in Heart Rate, Change from Baseline in Systolic Blood Pressure, Change in Weight, Maximum Serum Concentration (Cmax) of Etelcalcetide, Mean Change from Baseline in Predialysis iPTH from Baseline during the EAP, Number of Participants who Experienced Adverse Events (AEs), Percentage Change from Baseline in Corrected Total Serum Ca from Baseline During the EAP
Renal